Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data

Background: Non-randomized studies have investigated multi-agent gemcitabine-based neo-adjuvant therapies (GEM-NAT) in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC). Treatment sequencing and specific elements of neoadjuvant treatment are still under investigation. The present meta...

Full description

Bibliographic Details
Main Authors: Francesco Giovinazzo, Fiammetta Soggiu, Jin-Young Jang, Eva Versteijne, Geertjan van Tienhoven, Casper H. van Eijck, Youngmin Han, Seong Ho Choi, Chang Moo Kang, Mark Zalupski, Hasham Ahmad, Sarah Yentz, Scott Helton, J. Bart Rose, Chie Takishita, Yuichi Nagakawa, Mohammad Abu Hilal
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
gemcitabine
gemcitabine-based neoadjuvant
neoadjuvant treatment of pancreatic cancer
Pancreatic ductal adenocancinoma
Borderline resectable pancreaic adenocarcinoma
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01112/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01112/full

Similar Items